Clinical trial
Feasibility of [¹⁸F]-Fluoromisonidazole (FMISO) in Assessment of Malignant Brain Tumors
NCT03649880 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Feasibility of [¹⁸F]-Fluoromisonidazole (FMISO) in Assessment of Malignant Brain Tumors
- Lead sponsor
- OHSU Knight Cancer Institute
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- June 1, 2019
- Completion date
- January 31, 2030
- Enrollment
- 77 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
idh wild type glioblastoma